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AMD  age-related macular degeneration 
CNV  choroidal neovascularization 
CTGF  connective tissue growth factor 
DMSO dimethyl-sulfoxide 
EMA  European Medicines Agency 
ETDRS early treatment of diabetic retinopathy study 
FDA  US Food and Drug Administration 
GA  geographic atrophy 
hPC-PL human pericytes from placenta 
HUVEC human umbilical vein endothelial cells 
IC50  half-maximal inhibitory concentration 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
nAMD  neovascular age-related macular degeneration 
OCT  optical coherence tomography 
PI3K  phosphoinositide 3-kinase 
PCR  polymerase chain reaction 
PLC- γ phospholipase γ 
PlGF  placental growth factor 
PDGF  platelet derived growth factor 
PRN  pro re nata 
MAPK  mitogen activated protein kinase 
RNA  ribonucleic acid 
RPE  retinal pigment epithelium 
SMA  smooth muscle actin 
XTT 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-
Carboxanilide 
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3 Introduction 
The scope of diseases affecting the macula is broad. As this special region provides 
the highest visual acuity of the retina, it has specific metabolic needs, especially in its 
central part, the fovea1. The retinal pigment epithelium (RPE), which provides 
metabolic support to the outer retina, has its highest RPE to photoreceptor density 
subfoveally2, and also choroidal thickness has been found to be highest in the foveolar 
region3-5. 
Due to these support mechanisms, aging of the healthy human retina, measured as 
photoreceptor loss, is paradoxically less pronounced in the fovea and parafoveal area 
than in the retinal periphery6,7. Conversely, in the case of decompensation of these 
support mechanisms, macular degeneration can cause rapid and severe loss of visual 
acuity8.  
Age-related macular degeneration (AMD) is the most frequent cause of irreversible 
visual impairment and blindness in the elderly9,10, affecting 8.7% of the world 
population between 45 and 85 years11. Due to demographic change, the number of 
people affected is expected to increase 1.5-fold within 20 years from 2020, equalling 
288 million by 204011.  
Clinically, AMD is defined by the accumulation of Drusen ≥ 63 µm on OCT imaging of 
the macula12. Drusen mainly contain lipid13 and seem to represent unprocessed debris 
of the visual cycle14. Following Drusen growth and accumulation, AMD progresses via 
the intermediate into the late stage, which is defined (I) as the ‘wet’ form characterized 
by the development of pathologic vessels growing from the choroid into the 
neuroretina, termed choroidal neovascularization (CNV); or (II) the ‘dry’ form, 
characterized by progressive atrophy of the retinal pigment epithelium, photoreceptors 
and choriocapillaris, termed geographic atrophy (GA)8,15. 
Visual decline is much more rapid and severe in the ‘wet’ compared to the ‘dry’ 
phenotype8,16. While the wet form makes up 10 to 15 % of all cases of AMD, it is 
responsible for severe visual disability in about 80 % of AMD patients. This is due to 
the results of pathologic angiogenesis as represented in CNV: fibrovascular disruption 
of the neuroretina, leakage of fluid and bleeding17. Therefore, management of AMD in 
its neovascular phenotype mainly represents the management of pathologic 
angiogenesis, i.e. the re-induction of vascular quiescence, the promotion of regression 
of pathologic vessels, and the prevention of vessel regrowth8. With the advent of 
Verteporfin photodynamic therapy in 1999, the risk of moderate and severe vision loss 
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secondary to neovascular AMD (nAMD) could be significantly diminished compared to 
the natural course, however not offering mean gains in mean visual acuity compared 
to baseline18,19. In 2006, the advent of the first intravitreal anti-VEGF antibody 
Ranibizumab (Novartis AG, Basel, Switzerland) revolutionized the treatment of nAMD, 
for the first time offering partial restoration of visual acuity lost due to neovascular 
disease during a follow-up of two years20,21. In the following, non-inferior clinical 
outcomes were also demonstrated for the antibody Bevacizumab, of which 
Ranibizumab is a fragment, during a follow-up of 5 years22.  
After a ten-year experience with anti-VEGF, two major limitations have however proven 
challenging in clinical practice. Firstly, the currently available anti-VEGF substances 
have to be re-injected frequently due to the chronicity of the disease and several 
mechanisms of drug clearance from the vitreous body23-25. In the pivotal phase three 
studies, Ranibizumab was therefore injected on a fixed interval of four weeks20,21, 
which is difficult to translate into clinical practice due to the burden on patients and 
health care providers alike, resulting in inconsistent reinjections and frequent 
discontinuation of therapy in real life26. According to current guidelines, in the case of 
newly diagnosed nAMD, an upload of three injections every four weeks is 
recommended and has been widely adopted worldwide8,27. While there is much 
consensus on this ‘induction phase’, intensity of treatment in the following 
‘maintenance phase’ has been highly debated28,29. In the beginning of anti-VEGF 
therapy, clinicians adopted a pro re nata (PRN) regimen, which, after the upload, 
moves to monthly monitoring and further treatment in the case of documented loss of 
visual acuity or OCT showing signs of disease reactivation, defined as re-injection 
criteria as proposed in the PrONTO study30. Experience gained in the following years 
however showed that (I) reactivation of CNV and recurrence of macular fluid is 
significantly associated with increased short and long-term loss of visual acuity31; and 
(II) that disease activity and thus intensity of therapy needed are highly individual30,32. 
Therefore, nowadays a ‘treat & extend’ regimen is recommended, which aims at 
individualizing treatment intervals and reducing control and injection visits while 
preventing recurrence of edema28,29. After an upload of three injections every four 
weeks, injections are performed at every follow-up visit, but treatment intervals are 
extended by two weeks in the case of successful disease management, i.e. no signs 
of macular fluid or CNV reactivation on OCT imaging. In the case of disease 
reactivation, e.g. recurrence of macular fluid on OCT, the treatment interval is 
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shortened by two weeks (minimum: 4 weeks). After achieving an interval of 12 weeks, 
anti-VEGF therapy might be considered to be stopped or, as disease reactivation is 
frequent, paused28,29. 
Although the treat & extend regimen allows for a reduction of control and injection visits 
and has been shown to obtain superior results to PRN injections27, repeated need of 
diagnostic and therapeutic interventions over many years poses a gigantic 
socioeconomic burden33,34. Further development of anti-VEGF substances has 
therefore aimed at improved and prolonged anti-neovascular activity; in 2012, 
bimonthly intravitreal Aflibercept was shown to be non-inferior to monthly Ranibizumab 
treatment, as second substance gaining approval for the treatment of nAMD35,36. 
However, differences in injection rates and socioeconomic cost between Ranibizumab 
and Aflibercept are of little clinical significance34,37, with 4.9 (Ranibizumab) vs. 5.2 
(Aflibercept) injections in the first year, as reported in the US37 or by preliminary data 
of the RIVAL trial (ongoing).  
Secondly, in addition to the high intensity of treatment, mean long-term visual acuity 
results in nAMD are poor in spite of anti-VEGF therapy. Data from the Seven-Up trial, 
for the first time offering substantial follow-up beyond two years and indicating a mean 
loss of 8.2 ETDRS letters after seven years33, was recently confirmed by the five-year 
results of the comparison of age-related macular degeneration treatment trials (CATT), 
which indicate a mean loss of 10.8 letters in comparison to the gains at year two33. In 
addition to this mean loss in visual acuity, about ten percent of patients are classified 
as anti-VEGF non-responders, losing more than 15 ETDRS letters at two years20,28,38.  
Both the high intensity of treatment, caused by repeated CNV reactivation, as well as 
the poor long-term outcomes, which are clearly attributed to the presence of 
intraregional fluid, scarring and atrophy, are signs of not sufficiently managed CNV 
activity31. Therefore, the evaluation of new therapy strategies for nAMD is of great 
interest, aiming at improving long-term visual outcome, and secondly lowering the 
treatment burden for patients and health care professionals alike.  
In addition to VEGF, a variety of growth factors has been shown to play a major role in 
nAMD, including platelet derived growth factor (PDGF), placenta growth factor (PlGF) 
and connective tissue growth factor (CTGF), among others39. Of these, the combined 
inhibition of VEGF and PDGF has been studied most extensively in in vitro and in vivo 
oncologic and ophthalmologic studies40-42. The interaction between these two growth 
factors is highly dependent on the vascular status, as quiescent vessels have other 
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metabolic needs than vessels involved in angiogenesis and vascular remodeling43. 
While physiological vascular quiescence is mediated by simultaneous, concerted 
VEGF/PDGF action, angiogenesis in health and disease requires sequential growth 
factor signalling, as it is a result of firstly vessel formation (mediated by endothelial 
cells and VEGF) and secondly vessel maturation (mediated by cells of the vascular 
wall, mainly pericytes and PDGF)43,44.  
Vessel formation in CNV is a result of sprouting angiogenesis, which can be divided 
into four steps45. Firstly, endothelial cells loosen their intercellular contacts and secrete 
matrix metalloproteinases, releasing themselves and cells of the vascular wall from the 
basement membrane45. Secondly, endothelial cells migrate into the interstitium45. 
While so-called tip cells lead the vascular sprout, their release of VEGF directed 
backwards causes so-called stalk cells to follow46. In the third step, the cells proliferate, 
finally resulting in the formation of tube-like structures, after which the establishment 
of a new basement membrane follows in the fourth step45. All of these mechanisms 
are mainly VEGF-dependent, and current anti-neovascular therapy is believed to 
convey its therapeutic properties by the interference with them, reducing vascular 
leakage and thus retinal edema, inducing partial vessel regression, and delaying CNV 
regrowth47. 
After these VEGF-driven steps representing vessel formation, PDGF driven vessel 
maturation establishing stable vascular constructs and endothelial cell VEGF 
independence is mediated by the recruitment of pericytes and smooth muscle cells44. 
Pericytes mediate this maturation by mechanical stabilization and the paracrine 
secretion of endothelial cell supporting growth factors, mainly Angiopoietin 1 and 
VEGF48. As pericyte-derived VEGF is secreted in an iuxtacrine/paracrine fashion, 
common intravitreal anti-VEGF neutralization cannot sufficiently exert inhibitory effects 
in this case49,50. Pericytes themselves are VEGF-independent44. Thus, pericyte 
covered segments of CNV are supposed to be partially anti-VEGF resistant, rendering 
a substantial percentage of the CNV irresponsible to nowaday’s standard of care51. 
This is supported by ongoing OCT angiography studies, as for the first time reported 
by Huang et al.47, which show that CNV size can be reduced by anti-VEGF, but CNV 
cannot be forced into complete regression, and that regrowth from persisting vascular 
beds re-occurs as anti-VEGF levels drop with time. To start angiogenesis, hypoxic 
regions of the retina release VEGF, inducing excess formation of new vessels. As 
reported for the first time by Benjamin et al.52, pericyte recruitment and association with 
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newly formed vessels then lag a few days behind. This opens a plasticity window for 
vascular remodelling, as pericyte-naïve tubes are forced into regression when anti-
VEGF levels drop because the newly vascularized retina is not hypoxic anymore52. 
Only larger vascular trunks, having undergone pericyte coverage, then persist in spite 
of VEGF depletion, and form the new vascular bed43. 
Blockage of the PDGF pathway can disrupt endothelial cell-pericyte communication40. 
In this way, addition of anti-PDGF substances to the arsenal against nAMD might 
interfere with pericyte recruitment to neovessels, and secondly probably strip pericytes 
off matured CNV segments. This provides a very interesting new strategy to manage 
CNV in AMD, as exposing a more vulnerable pericyte-naïve CNV to anti-VEGF would 
improve neovascular management44.  
The PDGF family consists of five polypeptides of 30 kilodalton (kDa)53. Signaling is 
mediated in a dimerized fashion, resulting in the subforms PDGF-AA, -BB, -CC, -DD 
and the mixed form -AB53. In the eye, signaling is predominantly mediated by PDGF-
BB54-56. Large global, multicenter, randomized, prospective, double-masked, 
controlled superiority trials have been designed to study the effect of combined anti-
VEGF and anti-PDGF-BB inhibition on nAMD41,42. Combined with Ranibizumab or 
Aflibercept treatment, PDGF inhibition was achieved by the additional intravitreal 
injection of Pegpleranib (Fovista; Ophtotech, New York USA), an aptamer designed to 
bind PDGF-BB41,42. Published data from the phase IIb trial showed promising results 
with 62% visual gain in the combination arm (1.5 mg Pegpleranib) compared to 
Ranibizumab mono, translating into 10.6 vs. 6.5 early treatment of diabetic retinopathy 
study (ETDRS) letters after 24 weeks41. However, the following phase III study failed 
to confirm superiority57. Additionally, the sequential injection of both agents at a volume 
of 0.05 ml in the same visit, equaling twice the volume of nowadays standard of care, 
required thorough post-interventional monitoring of intraocular pressure in all study 
patients and IOP-lowering therapy in some (own experience).    
The first anti-VEGF substance to enter the clinic was the aptamer Pegaptanib in 2004 
(Macugen; EyeTech Pharmaceuticals, New York, USA)58. However, the later 
antibodies Ranibizumab and Aflibercept have been shown to be of greater potency in 
suppressing nAMD59,60. In a similar fashion, PDGF suppression in pericytes has been 
shown to be of high anti-neovascular effect in vitro and in vivo40,61, but might not be 
thoroughly addressed by the aptamer Pegpleranib in humans in vivo. This is supported 
by the fact that PDGF, supporting pericyte coverage of neovessels, is secreted as 
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growth factor in a paracrine fashion and bound to heparan sulfate proteoglycans on 
the endothelial surface or in the matrix surrounding pericytes, thus being less exposed 
to neutralization by aptamers or antibodies in the vitreous body62. 
An alternative option to modulate growth factor signaling is to inhibit the growth factor’s 
receptor to prevent the intracellular downstream cascade, a principle which should not 
be affected by paracrine secretion or heparan sulfate proteoglycan binding63-65. 
Biochemically, VEGF and PDGF, as well as their receptors, share major ultrastructural 
similarities going so far that VEGF-A has been shown to be able to signal via PDGF 
receptors in mesenchymal stem cells66. Therefore, many tyrosine kinase inhibitors 
simultaneously modulating VEGF- and PDGF-receptor signaling are available67. For 
the experimental anti-VEGF/PDGF inhibition reported in Publication I and II herein, the 
tyrosine kinase inhibitor Axitinib (Inlyta; Pfizer, New York, USA) was chosen as it 
features the lowest half-maximal inhibitory concentration (IC50) for VEGF receptors 1, 
2 and 3 (0.1 – 0.3 nM) and PDGFR-ββ (1.6 nM) of all anti-VEGF/PDGF tyrosine kinase 
inhibitors available clinically; moreover, good biocompatibility with ocular tissue is 
suggesting it for intravitreal use67. While Axitinib also inhibits c-KIT, these effects on 
pericytes can be neglected as pericytes do not express c-KIT68. Axitinib has been 
approved by both the European Medicines Agency (EMA) and the US Food and Drug 
Administration (FDA) for the treatment of advanced renal cell carcinoma in 201269.  
 
Publication I entitled “Combined VEGF and PDGF inhibition for neovascular AMD: anti-
angiogenic properties of axitinib on human endothelial cells and pericytes in vitro” 
seeks to answer the question whether VEGF/PDGF-receptor inhibition using Axitinib 
poses a feasible alternative method of anti-angiogenesis against both effectors of 
CNV, namely endothelial cells and pericytes. Treating them with ascending doses of 
Axitinib, cellular angiogenic behaviour under VEGF- and PDGF-stimulation was 
evaluated in established models of angiogenesis. 
Publication II entitled “Combined VEGF/PDGF inhibition using axitinib induces 
alphaSMA expression and a pro-fibrotic phenotype in human pericytes” is designed to 
evaluate the morphologic and structural changes in the target cell of anti-PDGF, the 
pericyte, in response to combined anti-VEGF/PDGF inhibition. Treating pericytes with 
Axitinib, its effects on pericyte cytoskeleton, mRNA and protein expression of pro-
fibrotic a-smooth muscle actin (a-SMA) and pro-fibrotic behaviour were evaluated 
using established models of cellular wound healing.  
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4 Summary 
In this in vitro model of nAMD, the influence of combined anti-VEGF/PDGF receptor 
inhibition on endothelial cells and pericytes was investigated. Both cell types are 
heavily involved in macular neovascularization in nAMD, which, left untreated or 
managed insufficiently, leads to atrophy and macular subretinal fibrosis, causing end 
stage subretinal fibrosis and severe vision loss70,71. Offering the lowest combined IC50 
for VEGF receptors 1–3 and PDGF receptor ββ72, providing good ocular 
biocompatiblity72 and being approved by FDA and EMA for the use in humans69, the 
tyrosine kinase inhibitor axitinib was used to assess the impact of anti-VEGF/PDGF on 
macular neovascularization and fibrotic damage resulting from angiogenesis.  
In vitro, axitinib reduced VEGF-driven cellular mechanisms of angiogenesis, consisting 
of endothelial cell migration, ECM adhesion, subsequent proliferation and tube 
formation, resulting in a 112 % reduction of VEGF-induced tube length. While 
established anti-VEGF intravitreal therapy with Ranibizumab, Aflibercept or 
Bevacizumab is already offering these mechanisms of action, about 10-15 % of 
patients do not show an adequate response to current treatment20,28,38. For these 
patients, Axitinib shows a promising in vitro profile as a possible future alternative 
therapy modulating endothelial cell driven angiogenesis using growth factor receptor 
inhibition instead of growth factor elimination.  
Moreover, axitinib allowed to expand the anti-angiogenetic spectrum beyond anti-
VEGF towards PDGF and thus pericyte inhibition. PDGF driven pericyte proliferation 
and migration were significantly reduced, neutralizing the PDGF stimulated effect – 
causing a reversion of PDGF directed chemotaxis into a seemingly random 
chemokinesis, and inhibition of the PDGF driven proliferatory boost. A choroidal 
neovascularization (CNV) consisting of established endothelial tubes secretes PDGF 
to attract pericytes, which then in turn stabilize the tubes mechanically and via growth 
factor secretion48. By limiting pericyte proliferation and migration towards the CNV by 
blocking the PDGF pathway, axitinib might render endothelial cell-only CNV more 
vulnerable due to the lack of pericyte stabilization, which might prolong anti-VEGF 
action and force the endothelial tubes into regression. This way, clinical management 
of patients with nAMD would allow for a step towards CNV ablation instead of constant 
CNV persistence with constant regrowth after a drop of pharmacological compounds 
in the vitreous body, which at the moment requires continuous retreatment. Another 
additive effect of combined anti-VEGF/PDGF therapy observed was the reduction of 
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fibrovascular-like tissue surrounding endothelial tubes on basement membrane gels 
(up to -62 %). Scar material in macular fibrosis increases the more fibrovascular tissue 
a CNV generates; prevention of scarring thus requires a reduction of fibrovascular 
tissue71. As PDGF is a major player in fibrotic processes, from a future clinical 
perspective Axitinib treatment might reduce the fibrovascular burden accompanying 
CNV, clearing the subretinal space from debris causing photoreceptor disruption, 
atrophy, and visual loss70,71.  
On the contrary, from a clinical perspective the imagination of uncontrolled pericyte 
ablation might be a threat to the stability of healthy retinal vessels, as pericyte-drop out 
is a well-known first feature of diabetic microangiopathy73. In a second step, we 
therefore examined the influence of combined anti-VEGF/PDGF inhibition on pericyte 
morphology, dedifferentiation and cellular function – which is crucial, as steady 
endogenous PDGF levels are crucial to maintain endothelial-pericyte contact and 
crosstalk44. 
After 24 hours, pericytes treated with non-toxic concentrations of axitinib showed an 
increase in the actin cytoskeleton with focal densities already. As proven on 
messenger RNA and protein level, this change in phenotype is associated with a 
significant induction of a-smooth muscle actin. In other organs of the human body, 
mainly the lung and kidney, dedifferentiation of pericytes into a similar phenotype has 
been shown to be an important source of myofibroblasts, driving pathological fibrosis 
- a mechanism for which a-SMA upregulation, as in our case, is patho-
gnomonic51,68,74,75. 
In our model, however, continued anti-VEGF/PDGF inhibition diminished the fibrotic 
behaviour of these transdifferentiated proto-myofibroblasts, namely scratch wound 
closure and collagen gel contraction. This might at first sound paradoxical, as migration 
and contraction are known to be promoted by an induction of contractile fibres of the 
cytoskeleton76. It has been shown, however, that both contraction77,78 and 
migration79,80 depend on signalling via phospholipase γ (PLC-γ), and contraction 
additionally on protein kinase C (PKC) and phosphoinositide 3-kinase (PI3K)77. 
Therefore, continued upstream blockage of PDGF-BB receptors via axitinib seems to 
diminish the activation of the downstream effectors PLC-γ, PKC and PI3K, reducing 
the fibrotic processes mentioned above in spite of the phenotypic disposition of 
dedifferentiated pericytes to do so. 
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Criticism on our study might arise due to the fact that we used a VEGF/PDGF receptor 
tyrosine kinase inhibitor instead of an antibody or an aptamer, as used pre-
clinically41,54. We however believe that this was the better choice as axitinib is approved 
clinically and has been proven effective in inhibiting VEGF and PDGF in humans64,69. 
In addition, it allowed for a more reproducible inhibition of PDGF signalling as PDGF 
mediating pericyte survival and attachment is secreted in a para/iuxtacrine fashion, 
and mostly bound to molecules around the pericyte itself, e.g. heparan sulphate 
proteoglycans; thus, vessel stabilizing, physiological PDGF is difficult to eliminate via 
antibodies or aptamers in cell culture medium62. The importance of this is also 
supported by the fact that exogenous PDGF in vivo does not support pericyte stability, 
but induces pericyte detachment from maturing vessels, as it is not delivered in the 
physiological para/iuxtacrine fashion52. 
In conclusion, this work strengthens the dichotomy of PDGF and PDGF inhibition: As 
PDGF is strongly involved in vascular formation and maintenance, PDGF inhibition 
represents a promising new strategy of retinal anti-angiogenesis by targeting pericyte-
driven CNV stabilization. As, however, PDGF is pivotal for pericyte survival and 
differentiation, PDGF inhibition induces pericyte dedifferentiation towards a 
myofibroblastic phenotype44,51. Beyond its involvement in angiogenesis, in this case 
PDGF signalling takes on its pivotal role in fibrotic mesenchymal responses62,68,81. 
From a future clinical perspective of CNV management in nAMD, anti-PDGF tyrosine 
kinase activity via axitinib might be capable to reduce pericyte recruitment to growing 
CNV and strip pericytes off established CNV, rendering CNV more vulnerable to anti-
VEGF. Additionally, axitinib might lead to a reduction of perivascular ECM formation 
around endothelial tubes, probably owing to the function of PDGF as modulator of the 
ECM81. On the other hand, PDGF deprived pericytes might undergo dedifferentiation 
into proto-myofibroblasts, resulting in an increase of pro-fibrotic cells in the macula82. 
These cells, however, seem to be less prone to fibrosis under continued anti-
VEGF/PDGF combination treatment. Therefore, continued anti-VEGF/PDGF activity 
might be needed beyond its anti-neovascular properties to limit consecutive fibrotic 
responses. A similar switch between angiogenesis and fibrosis has been described for 
diabetic retinopathy, termed the ‘angiofibrotic switch’83.  
In summary, pericyte stabilization of CNV is hypothesized to be a major contributor to 
the high intensity and limited outcomes of state-of-the-art anti-VEGF therapy in 
nAMD41,54. In this context, our in vitro data advocate that a combined anti-VEGF/PDGF 
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intravitreal therapy might improve the management of pathologic neovascularization, 
prolonging treatment intervals and maybe also offering better long-term visual acuity. 
Further evidence, including in vivo animal studies are definitely needed. Figuratively 
speaking, however, combined VEGF/PDGF inhibition might offer the opportunity to 
tackle the CNV by the root, and not to just constantly prune it.  
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5 Zusammenfassung (deutsche Version) 
Anhand eines in vitro Zellkulturmodells der neovaskulären AMD (nAMD) wurde in 
dieser Arbeit untersucht, welchen Einfluss eine kombinierte Inhibition der beiden 
Wachstumsfaktoren vascular endothelial growth factor (VEGF) und platelet derived 
growth factor (PDGF) auf Endothelzellen und Perizyten ausübt. Beide Zelltypen sind 
verantwortlich für die Bildung makulärer choroidaler Neovaskularisationen (CNV), die 
unbehandelt zum Endstadium der nAMD, der submakulären Fibrose, und einer daraus 
resultierenden hochgradigen Sehminderung führen70,71. Um den Effekt einer 
kombinierten VEGF/PDGF-Inhibition auf makuläre Neovaskularisationen und die aus 
der Angiogenese resultierende Fibrose zu untersuchen, wurde der Tyrosinkinase-
Inhibitor Axitinib ausgesucht. Axitinib eignet sich für diese Fragestellung besonders, 
da diese Substanz die niedrigste klinisch verfügbare mittlere inhibitorische 
Konzentration (IC50) für die VEGF-Rezeptoren 1–3 und den PDGF ββ-Rezeptor72 
bietet, eine gute okuläre Biokompatibilität aufweist72, und nicht zuletzt durch die FDA 
und EMA für den klinischen Einsatz am Menschen zugelassen ist69.  
In vitro führte Axitinib zu einer signifikanten Reduktion maßgeblicher endothelialer 
Angiogeneseprozesse, nämlich der Endothelzellmigration, der Adhäsion, Proliferation 
und Bildung kapillarähnlicher Fortsätze (tube formation). Die Länge dieser 
kapillarähnlichen Fortsätze („tubes“), die unter VEGF-Stimulation auf Basalmembran-
Gelen untersucht wurde, zeigte sich nach Behandlung mit Axitinib um 112 % reduziert. 
Obwohl eine ähnliche Wirksamkeit auch von den im klinischen Einsatz befindlichen 
Substanzen Ranibizumab, Aflibercept und Bevacizumab in solch einem 
experimentellen Aufbau zu erwarten ist, bieten unsere in vitro-Daten Hinweise, dass 
Axitinib eventuell als Therapiealternative für die 10-15 % der Patienten in Frage käme, 
die in der Literatur als Non-Responder auf den heutigen Therapiestandard – nämlich 
reine Wachstumsfaktorinhibition – gelten20,28,38. Für diese Patienten zeigt Axitinib ein 
vielversprechendes in vitro-Profil, um die durch Endothelzellen vermittelte 
Angiogenese nicht nur mittels Wachstumsfaktor-Blockade, sondern mittels 
entsprechender Rezeptormodulation einzuschränken. 
Weiterhin erlaubte es Axitinib als breit wirksamer Tyrosinkinaseinhibitor, das 
pharmakologische Spektrum der Behandlung für die nAMD über anti-VEGF hinaus zu 
erweitern. Anders als anti-VEGF-Hemmer im klinischen Einsatz ist Axitinib auch gegen 
den Wachstumsfaktor PDGF wirksam, der in der Angiogenese ein wichtiges 
Signalmolekül für Zellen der Gefäßwand, hauptsächlich Perizyten darstellt. Während 
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der Entstehung einer CNV bilden Endothelzellen zunächst Kapillaren, die in der Folge 
PDGF sezernieren, um Perizyten zu rekrutieren; diese stabilisieren die neuen 
Kapillaren mechanisch und mittels Wachstumsfaktorsekretion, um sie damit vor einer 
Rückbildung durch Entzug von VEGF zu schützen48. In vitro konnte Axitinib sowohl die 
PDGF-abhängige Proliferation, als auch Migration der Perizyten erfolgreich inhibieren. 
Da PDGF den wichtigsten Proliferationsimpuls und das wichtigste Chemokin im 
Rahmen dieser Rekrutierung von Perizyten Richtung CNV darstellt, könnte Axitinib 
eventuell auch in Zukunft in vivo die gerichtete Chemotaxis zur CNV in eine 
ungerichtete Chemokinesis umwandeln, und die Zahl der Perizyten auf der sich 
bildenden CNV deutlich verringern. Somit könnte Axitinib die nur aus Endothelzellen 
bestehende CNV deutlich anfälliger für anti-VEGF machen, da keine Perizyten-
abhängige mechanische und über Wachstumsfaktoren vermittelte Stabilisierung des 
entstehenden Gefäßes bestünde. Auf diese Weise könnte eine kombinierte anti-
VEGF/PDGF-Inhibition in Zukunft eine echte Rückbildung der CNV ermöglichen, 
während unter Therapie mit den bisherigen anti-VEGF-Substanzen von Perizyten 
besetzte CNV-Gefäßstümpfe persistieren, aus denen neue Kapillaren sprossen, 
sobald die anti-VEGF-Wirkspiegel im Glaskörper sinken. Die Notwendigkeit der 
stetigen Wiederbehandlung könnte somit in Zukunft potentiell vermieden werden.  
Als weiterer Zusatznutzen gegenüber anti-VEGF als Monotherapie zeigte sich, dass 
Axitinib die Menge fibrovaskulären Gewebes um kapilläre endotheliale Strukturen auf 
Basalmembran-Gelen um bis zu 62 % reduzieren konnte. Um eine makuläre Fibrose 
zu verhindern, muss die Bildung fibrovaskulären Materials reduziert werden71. Da 
PDGF stark in Signalwege involviert ist, die fibrotisches Material produzieren, könnte 
Axitinib in Zukunft die Fibrosierung einer CNV reduzieren. Dadurch könnten 
Photorezeptoren und damit Sehvermögen besser besser erhalten bleiben70,71.  
Perizyten sind für eine gesunde Netzhautvaskulatur unerlässlich; deshalb ist auf der 
anderen Seite eine unkontrollierte PDGF-Deprivation retinaler Perizyten an gesunden 
Gefäßen streng zu vermeiden, da ein Perizytenverlust eines der ersten Zeichen der 
diabetischen Mikroangiopathie darstellt73. Aus diesem Grund untersuchten wir in 
einem zweiten Schritt, welche Auswirkung eine kombinierte anti-VEGF/PDGF-
Inhibition auf die perizytäre Morphologie, Dedifferenzierung und Zellfunktion hatte. 
Dies ist klinisch hochrelevant, da dauerhafte endogene PDGF-Level vonnöten sind, 
um die physiologische Zusammenarbeit von Endothelzelle und Perizyt 
sicherzustellen44.  
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Weniger als 24 Stunden nach einer Behandlung mit nicht-toxischen Dosen von Axitinib 
zeigte sich in den Perizyten schon eine Induktion des Aktin-Zytoskeletts mit fokalen 
Zytoskelett-Verdichtungen. Wir konnten auf mRNA- und Proteinebene bestätigen, 
dass diese Umbauvorgänge mit einer signifikanten Induktion von a-smooth muscle 
Aktin (aSMA) assoziiert sind. In anderen Organen des menschlichen Körpers, 
hauptsächlich der Lunge und Niere, wurde bereits nachgewiesen, dass solch 
dedifferenzierte Perizyten eine Hauptquelle von Myofibroblasten darstellen, die zu 
einer pathologischen, überschüssigen Fibrose führen; für diesen Mechanismus ist eine 
Hochregulation von aSMA pathognomonisch51,68,74,75. 
Trotz dieser Änderung des Phänotyps kam es in den nachfolgenden Zellversuchen zu 
einer Reduktion pro-fibrotischer Zellmechanismen im scratch wound- und 
Kontraktionsassay.  Dies mag zunächst paradox klingen, da beide Mechanismen von 
einer Hochregulierung kontraktiler Fasern begünstigt werden76. Es wurde allerdings 
gezeigt, dass zelluläre Kontraktion77,78 und Migration79,80 von der Signalweiterleitung 
mittels Phospholipase γ (PLC-γ), und Kontraktion alleine zusätzlich von einer 
Signalweiterleitung mittels Proteinkinase C (PKC) und Phosphoinositide 3-kinase 
(PI3K) abhängen77. Daher ist anzunehmen, dass eine Blockade des PDGF-
Signalweges die Aktivierung von PLC-γ, PKC und PI3K verringert, was zu einer 
Reduktion oben genannter fibrotischer Prozesse führt, obwohl die Zellmorphologie 
sich pro-fibrotisch präsentierte. 
An unserer Studie mag zu kritisieren sein, dass wir statt eines präklinischen anti-
PDGF-Antikörpers oder Aptamers einen Tyrosinkinase-Inhibitor nutzten41,55. Dies ist 
allerdings dadurch zu rechtfertigen, dass Axitinib bereits zugelassen ist und in anderen 
in vitro Modellen der okulären Angiogenese gut funktioniert64,69. Zusätzlich ist zu 
bedenken, dass das PDGF, das zum Überleben und zur Kommunikation zwischen 
Endothelzelle und Perizyt beiträgt, para/iuxtakrin sezerniert wird und zu Großteilen an 
Heparansulfate um den Perizyten gebunden ist; dadurch ist es schwer durch 
Antikörper oder Aptamere im Zellkulturmedium zu eliminieren62. Dies wird auch 
dadurch bekräftigt, dass in vivo exogenes PDGF nicht zur Stabilisierung des Perizyten 
beiträgt, sondern Perizyten von Gefäßwänden ablöst, da es nicht in der 
physiologischen para/iuxtakrinen Art sezerniert wird52. 
 
Zusammenfassend stärkt unsere Arbeit die Dichotomie von PDGF und PDGF-
Inhibition. Da PDGF essentiell für Angiogenese und vaskuläre Homöostase ist, 
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repräsentiert die PDGF-Inhibition eine vielversprechende Strategie gegen CNV bei 
nAMD. Da PDGF aber den wichtigsten Wachstumsfaktor für das Überleben und die 
Differenzierung von Perizyten darstellt, führt eine PDGF-Inhibition zur perizytären 
Dedifferenzierung in Richtung Myofibroblast44,51. In diesem Fall rückt die Rolle von 
PDGF als Modulator fibrotischer mesenchymaler Gewebereaktionen in den 
Vordergrund62,68,81. In einem möglichen zukünftigen klinischen Einsatz könnte Axitinib 
über eine zusätzliche PDGF-Inhibition die Rekrutierung von Perizyten zur CNV 
stoppen, CNV-assoziierte Perizyten von der CNV lösen, und dadurch die CNV 
intensiver gegenüber anti-VEGF exponieren. Zusätzlich könnte Axitinib die Menge des 
perivaskulären Gewebes reduzieren, das endotheliale Gewebestrukturen umgibt, da 
PDGF in seiner Funktion als Modulator der extrazellulären Matrix (ECM) gehemmt 
wird81. Auf der anderen Seite erfolgt als Reaktion auf den pharmakologischen PDGF-
Entzug eine Dedifferenzierung der Perizyten in Richtung proto-Myofibroblast, was die 
pro-fibrotische Zelllast in der Makula erhöht82. Wird die anti-VEGF/PDGF-Therapie 
jedoch fortgeführt, zeigt dieser Zelltyp eine untypischer Weise geringe Aktivierung pro-
fibrotischer Zellprozesse. Deshalb könnte die kombinierte anti-VEGF/PDGF-Therapie 
im klinischen Einsatz über ihre anti-angiogene Funktion hinaus eine große Rolle 
spielen, um aus Angiogenese resultierende fibrotische Prozesse zu modulieren, wie 
man es vom ‘angiofibrotischen switch’ in der diabetischen Retinopathie her kennt83.  
Es ist davon auszugehen, dass die perizytäre Stabilisierung der CNV zur hohen 
Therapieintensität der derzeitigen anti-VEGF-Therapie und bisher limitierten Langzeit-
Visusprognose beiträgt41,54. In diesem Zusammenhang machen unsere in vitro-Daten 
Hoffnung, dass Axitinib möglicherweise auch klinisch in Zukunft längere 
Therapieintervalle und einen besseren Erhalt der Sehfunktion zulassen könnte. 
Weitere Studien, insbesondere im Tiermodell sind nötig, um die breite Anwendbarkeit 
weiter zu prüfen. Eine kombinierte VEGF/PDGF-Inhibition könnte jedoch die 
Möglichkeit bieten, über die Induktion einer vaskulären Regression die CNV kausal zu 
therapieren, statt nur mit wiederholten Re-Injektionen einen kurzfristigen Effekt auf das 
erneute Gefäßwachstum auszuüben. 
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